Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17848307 | 1.00 | PPARG (0.52) | PPARGUSP2SMN1; SMN2TP53HPGD | |
| SCHEMBL17848245 | 0.94 | PPARG (0.46) | PPARGUSP2SMN1; SMN2TP53LCK | |
| SCHEMBL17859163 | 0.94 | PPARG (0.51) | PPARGUSP2SMN1; SMN2TP53HPGD | |
| SCHEMBL17848273 | 0.94 | PPARG (0.46) | PPARGUSP2SMN1; SMN2TP53LCK | |
| SCHEMBL17848187 | 0.94 | PPARG (0.62) | PPARGUSP2SMN1; SMN2 | |
| SCHEMBL17848189 | 0.94 | PPARG (0.62) | PPARGUSP2SMN1; SMN2 | |
| SCHEMBL17821305 | 0.93 | PPARG (0.48) | PPARGUSP2SMN1; SMN2LCKKMT2A | |
| SCHEMBL17821303 | 0.93 | PPARG (0.48) | PPARGUSP2SMN1; SMN2LCKKMT2A | |
| SCHEMBL17848301 | 0.91 | PPARG (0.53) | PPARGUSP2SMN1; SMN2TP53HPGD | |
| SCHEMBL17848183 | 0.91 | PPARG (0.53) | PPARGUSP2SMN1; SMN2TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342021-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, LLC | 2017-11-30 | — | — | US | claimed |
| EP-3233070-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | claimed |
| WO-2016099452-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | claimed |
| US-20170342021-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, LLC | 2017-11-30 | — | — | US | disclosed |
| US-20170342021-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, LLC | 2017-11-30 | — | — | US | disclosed |
| US-20170342021-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, LLC | 2017-11-30 | — | — | US | disclosed |
| EP-3233070-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017106520-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | ADT PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2016099452-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | ADT PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342021-A1 | RAS-INHIBITING INDENYL ACETAMIDE COMPOUNDS, COMPOSITIONS, AND USES | KRAS, NRAS, HRAS | PPARG 2635/4885USP2 2111/4885SMN1; SMN2 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.